Drugmakers including GSK, Novartis, Eli Lilly, and Sanofi are moving beyond administrative automation to deploy artificial intelligence for identifying safety risks and designing novel compounds. Sanofi managed to shave at least one year off the development of an asthma therapy by bypassing a conventional dose-selection study. However, the slow pace of human trials and regulatory reviews continues to constrain the speed of bringing newly discovered therapies to the commercial market.
Key points
Early-stage drug discovery cycles are being reduced by as much as half through artificial…: Early-stage drug discovery cycles are being reduced by as much as half through artificial intelligence molecule design and screening.
Pharmaceutical companies believe their decades of proprietary data provide an essential a…: Pharmaceutical companies believe their decades of proprietary data provide an essential advantage over outside technology entrants.
Accelerated early discovery may not shorten overall drug delivery timelines due to persis…: Accelerated early discovery may not shorten overall drug delivery timelines due to persistent bottlenecks in clinical trials and regulatory approvals.
Sources checked by our analysis pipeline: 1
NEW YORK/LONDON, Nov 20 : Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic, according to their top scientists.
GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi all say they have moved beyond less glamorous tasks for AI like preparing regulatory filings. They are now using the technology for designing molecules, sorting out the most promising ones, and identifying safety risks.
“There is no part of the discovery through development pipeline where we are not using AI,” AstraZeneca executive Sharon Barr said.
Some of the scientists say decades of drug discovery experience and data give them an advantage over AI companies like Anthropic, which is gearing up to be a rival, partner or both, with a $1.5 trillion initial public offering this week.
In recent months, it opened its own laboratory and announced other investments, part of pushing AI to speed drug discovery.
Global healthcare corporations are accelerating their research pipelines by adopting advanced computational methods to identify viable medical treatments faster. Industry leaders emphasize that these efficiency gains allow scientists to bypass lengthy traditional experimental phases and advance therapies toward development more rapidly. Ultimately, this technological shift holds the potential to significantly reduce the overall time needed to evaluate and prepare novel medicines for patients.
The rapid escalation in value underscores intense investor enthusiasm for ventures led by prominent artificial intelligence researchers. Backing from this latest capital injection provides the Chinese startup with substantial resources to accelerate its technology development in a competitive market. The capital injection highlights how quickly top-tier technical leadership can attract massive market premiums.
The Cupertino tech giant's stock experienced an early boost following the discovery of specialized technical openings. These engineering roles point toward an internal effort to construct an agentic artificial intelligence platform. Such an initiative indicates the firm is preparing to directly challenge competing autonomous assistants across the technology sector.